Biomedical applications of yeast- a patent view, part one: yeasts as workhorses for the production of therapeutics and vaccines

References

• Feldmann H. Yeast: molecular and cell biology. Germany: Wiley-Blackwell; 2011.
   Google Scholar
• Kocková-Kratochvílová A. Yeasts and yeast-like organisms. Germany: VCH Verlagsgesellschaft; 1990.
   Google Scholar
• Mewes H, Albermann K, Bähr M, et al. Overview of the yeast genome. Nature. 1997;387:7–8.
   PubMed Web of Science ®Google Scholar
• Saccharomyces cerevisiae promoter database (http://rulai.cshl.edu/SCPD/)
   Google Scholar
• Saccharomyces genome database ( SGD: http://www.yeastgenome.org)
   Google Scholar
• Lindegren CC. The yeast cell: its genetics and cytology. USA: Educational Publishers; 1949.
   Google Scholar
• Cherry JM, Ball C, Weng S, et al. Genetic and physical maps of Saccharomyces cerevisiae. Nature. 1997;387:67.
   PubMed Web of Science ®Google Scholar
• Mattanovich D, Branduardi P, Dato L, et al. Recombinant protein production in yeasts. 2012; 824: 329–358.
   Google Scholar
• Bill RM. Recombinant protein subunit vaccine synthesis in microbes: a role for yeast? J Pharm Pharmacol. 2015;67:319–328.
   PubMed Web of Science ®Google Scholar
• Shouval D. Hepatitis B vaccines. J Hepatol. 2003;39:70–76.
   PubMed Web of Science ®Google Scholar
• de Wilde M, Cabezon T, Harford N, et al. Production in yeast of hepatitis B surface antigen by R-DNA technology. Dev Biol Stand. 1984;59:99–107.
   Google Scholar
• Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine. 2007;25:3001–3006.
   PubMed Web of Science ®Google Scholar
• Aleem E. β-Glucans and their applications in cancer therapy: focus on human studies. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2013;13:709–719.
   PubMed Web of Science ®Google Scholar
• Auinger A, Riede L, Bothe G, et al. Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body’s defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects. Eur J Nutr. 2013;52:1913–1918.
   PubMed Web of Science ®Google Scholar
• Ardiani A, Higgins JP, Hodge JW. Vaccines based on whole recombinant Saccharomyces cerevisiae cells. FEMS Yeast Res. 2010;10:1060–1069.
   PubMed Web of Science ®Google Scholar
• King TH, Guo Z, Hermreck M, et al. Construction and immunogenicity testing of whole recombinant yeast-based T-cell vaccines. Methods Mol Biol. 2016;1404:529–545.
   PubMedGoogle Scholar
• Çelik E, Çalık P. Production of recombinant proteins by yeast cells. Biotechnol Adv. 2012;30:1108–1118.
   PubMed Web of Science ®Google Scholar
• Laurent JM, Young JH, Kachroo AH, et al. Efforts to make and apply humanized yeast. Brief Funct Genomics. 2015;15(2):155–163.
   PubMed Web of Science ®Google Scholar
• Maitreya D, Marc G, Robert W, et al. Methods in Yeast Genetics and Genomics, 2015 Edition: A CSHL Course Manual. Cold Spring Harbor Laboratory Course Manual, 2015.
   Google Scholar
• Hinnen A, Hicks JB, Fink GR. Transformation of yeast. Proc Natl Acad Sci. 1978;75:1929–1933.
   PubMed Web of Science ®Google Scholar
• Kim H, Yoo SJ, Kang HA. Yeast synthetic biology for the production of recombinant therapeutic proteins. FEMS Yeast Res. 2015;15:1–16.
   PubMed Web of Science ®Google Scholar
• Ahmad M, Hirz M, Pichler H, et al. Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol. 2014;98:5301–5317.
   PubMed Web of Science ®Google Scholar
• Shay LK, Wegner EH, inventors; Phillips Petroleum Company, assignee. High methionine content Pichia pastoris yeasts. Patent US4439525A (EP0074123B1). 1984.
   Google Scholar
• Shay LK, inventor; Phillips Petroleum Company, assignee. Pichia pastoris yeast strains of enhanced tryptophan content. Patent US4707449A. 1987.
   Google Scholar
• Lair SV, Digan ME, inventors; Phillips Petroleum Company, assignee. Double auxotrophic mutants of Pichia pastoris and methods for preparation. Patent US4812405A. 1989.
   Google Scholar
• Takagi S, Tsutsumi N, Terui Y, et al., inventors; Novozymes A/S, assignee. Method for methanol independent induction from methanol inducible promoters in Pichia. Patent US8236528B2 (EP2106447B1, WO2008090211A1). 2012.
   Google Scholar
• Hartner F, Glieder A, inventors; Technische Universität Graz, Vtu-Engineering Planungs-Und Beratungsgesellschaft M.B.H., assignee. Mutant AOX 1 promoters. Patent WO2006089329A2 (EP2199389B1, US9012175). 2006.
   Google Scholar
• Cregg JM, Tolstorukov II, inventors; Keck Graduate Institute, Alder Biopharmaceuticals, Inc., assignee. P. pastoris ADH promoter and use thereof to direct expression of proteins. Patent US8222386B2 (WO2008063302A3). 2012.
   Google Scholar
• Jeffries TW, Bae JY, Lin BC, et al., inventors; Thomas William Jeffries, Bae Juyun, Lin Bernice Chin-Yun, Jennifer Rebecca Headman Van Vleet, assignee. Sugar transport sequences, yeast strains having improved sugar uptake, and methods of use. Patent US20090325241A1. 2009.
   Google Scholar
• Cregg JM, inventor; Research Corporation Technologies, Inc., assignee. Promoter for the Pichia pastoris formaldehyde dehydrogenase gene FLD1. Patent US6730499B1 (US20070298500). 2004.
   Google Scholar
• Hollenberg CP, Janowicz Z, inventors; Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH, assignee. DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses. Patent EP0299108B1 (US5389525). 1994.
   Google Scholar
• An Tingwu CY, Mingzhu P, Hongyuan L, et al., inventors; Korea Institute of Life Engineering, assignee. Auto-inducible sodium phosphate symporter promoter from Pichia pastoris and method for producing recombinant protein using it. Patent CN101415824A (EP2013342B1, US8080389). 2006.
   Google Scholar
• Vogl T, Glieder A. Regulation of Pichia pastoris promoters and its consequences for protein production. N Biotechnol. 2013;30:385–404.
   PubMed Web of Science ®Google Scholar
• Damasceno LM, Huang C-J, Batt CA. Protein secretion in Pichia pastoris and advances in protein production. Appl Microbiol Biotechnol. 2012;93:31–39.
   PubMed Web of Science ®Google Scholar
• Chang MD-T, Sheu -C-C, inventors; Simpson Biotech Co., Ltd., assignee. Nucleic acids for enhancing gene expression and use thereof. Patent US7785872B2 (US20070122876). 2010.
   Google Scholar
• Govindappa N, Sreenivas S, Periyasamy S, et al., inventors; Biocon Limited, assignee. Signal sequence for protein expression in Pichia pastoris. Patent US20160168198A1 (EP3027752A2, WO2015001460A3). 2014.
   Google Scholar
• Ciplys E, Slibinskas R, Sasnauskas K, et al., inventors; Uab Baltymas, assignee. Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems. Patent US20150191713A1 (EP2872644A4, WO2014011723A1). 2015.
   Google Scholar
• Callewaert N, De Schutter K, Tiels P, et al., inventors; Research Corporation Technologies, Vib, Vzw, Universiteit Gent, assignee. Nucleic acids of pichia pastoris and use thereof for recombinant production of proteins. Patent US20110021378A1 (US8440456, WO2010135678A1). 2011.
   Google Scholar
• Puxbaum V, Mattanovich D, Gasser B. Quo vadis? The challenges of recombinant protein folding and secretion in Pichia pastoris. Appl Microbiol Biotechnol. 2015;99:2925–2938.
   PubMed Web of Science ®Google Scholar
• Monod M, inventor; Centre Hospitalier Universitaire Vaudois (Chuv), assignee. Pichia pastoris deficient in endogenous secreted protease. Patent US8703444B2 (EP2513301A1, WO2011073883A1). 2014.
   Google Scholar
• Raymond CK, Vanaja E, inventors; Zymogenetics, Inc., assignee. Protease-deficient strains of Pichia methanolica. Patent US6153424 A. 2000.
   Google Scholar
• Roy SN, inventor; New York Blood Center, Inc, assignee. Production and secretion of recombinant fibrinogen by yeast. Patent WO1996007728A1 (EP0778884A1). 1996.
   Google Scholar
• Saraya R, Krikken AM, Kiel JA, et al. Novel genetic tools for Hansenula polymorpha. FEMS Yeast Res. 2012;12:271–278.
   PubMed Web of Science ®Google Scholar
• Abbas CA, Sibirny AA, Voronovsky AY, et al., inventors; Archer Daniels Midland Company, assignee. Alcoholic xylose fermentation at high temperatures by the thermotolerant yeast Hansenula polymorpha. Patent US20130084616A1 (WO2009076343A2). 2013.
   Google Scholar
• Hellmuth K, Lopez-Ulibarri R, Mayer AF, et al., inventors; DSMIP Assets B.V., assignee. Protein production process. Patent US6204012B1 (EP0911416B1). 2001.
   Google Scholar
• Nishi T, Teruyuki W, Ishiguro K, et al., inventors; Kaneka Corporation, assignee. Yeast for transformation and process for producing protein. Patent WO2012102171A1 (EP2669375A4). 2012.
   Google Scholar
• Rossolini GM, Riccio ML, Galeotti C, et al., inventors; Bioanalisi Centro Sud S.N.C., assignee. Vector for site-specific integration of heterologous DNA sequences into the rdn a sites of methylotrophic yeasts. Patent WO2003014363A1 (US20040241829). 2003.
   Google Scholar
• Wagner JM, Alper HS. Synthetic biology and molecular genetics in non-conventional yeasts: current tools and future advances. Fungal Genet Biol. 2016;89:126–136.
   PubMed Web of Science ®Google Scholar
• Dekker PJT, Edens L, Mpm DS, et al., inventors; DSM IP Assets B.V, assignee. Enzyme preparations yielding a clean taste. Patent WO2007060247A3 (EP2977453A1, US9011948). 2015.
   Google Scholar
• Jolink FJC, Schaap A, inventors; Dsm Ip Assets B.V., assignee. Liquid lactase compositions. Patent WO2015132349A1 (CA2939841A1). 2015.
   Google Scholar
• Spohner SC, Schaum V, Quitmann H, et al. Kluyveromyces lactis: an emerging tool in biotechnology. J Biotechnol. 2016;222:104–116.
   PubMed Web of Science ®Google Scholar
• van Ooyen AJ, Dekker P, Huang M, et al. Heterologous protein production in the yeast Kluyveromyces lactis. FEMS Yeast Res. 2006;6:381–392.
   PubMed Web of Science ®Google Scholar
• Van Den Berg JA, Ajj VO, Rietveld K, et al., inventors; Gist-Brocades Nv, assignee. Kluyveromyces as a host strain. Patent US6602682B1 (US4943529). 2003.
   Google Scholar
• Bankar AV, Kumar AR, Zinjarde SS. Environmental and industrial applications of Yarrowia lipolytica. Appl Microbiol Biotechnol. 2009;84:847–865.
   PubMed Web of Science ®Google Scholar
• Davidow LS, Franke AE, Dezeeuw JR, inventors; Pfizer Inc., assignee. Expression and secretion of heterologous proteins by Yarrowia lipolytica transformants. Patent EP0220864B1 (US4937189). 1993.
   Google Scholar
• Madzak C. Yarrowia lipolytica: recent achievements in heterologous protein expression and pathway engineering. Appl Microbiol Biotechnol. 2015;99:4559–4577.
   PubMed Web of Science ®Google Scholar
• Madzak C, Beckerich J-M. Heterologous protein expression and secretion in Yarrowia lipolytica. Yarrowia Lipolytica : Springer-Verlag Berlin Heidelberg. 2013; 25:1–76.
   Google Scholar
• Okkels JS, Jensen AD, Halkier T, et al., inventors; Maxygen Aps, assignee. Improved lysosomal enzymes and lysosomal enzyme activators. Patent WO2001049830A2 (EP1246915A2). 2001.
   Google Scholar
• Leblond Y, Mouz N, inventors; Laboratoires Mayoly Spindler, assignee. Method for producing lipase, transformed Yarrowia lipolytica cell capable of producing said lipase and their uses. Patent WO2007144475A1 (EP2035556B1). 2007.
   Google Scholar
• Faure JD, Nicaud JM, Bourdenx B, et al., inventors; Institut National de la Recherche Agronomique, assignee. Method for the production of very long chain fatty acids (VLCFA) by fermentation with a recombinant Yarrowia sp. Patent WO2011064393A1 (EP2516641A1, US20120226059). 2011.
   Google Scholar
• Park JN, Song Y, Kim JY, et al., inventors; Korea Research Institute Of Bioscience And Biotechnology, assignee. A novel YLMPO1 gene derived from Yarrowia lipolytica and a process for preparing a glycoprotein not being mannosylphosphorylated by using a mutated Yarrowia lipolytica in which YLMPO1 gene is disrupted. Patent US20100227362A1 (WO2008136564A1). 2010.
   Google Scholar
• Nielsen J. Production of biopharmaceutical proteins by yeast: advances through metabolic engineering. Bioengineered. 2013;4:207–211.
   PubMed Web of Science ®Google Scholar
• Kjeldsen TB, Inventor; Novo Nordisk A/S, assignee. Method for making human insulin precursors and human insulin. Patent WO2004085472A1. 2004.
   Google Scholar
• Madsen P, Kjeldsen TB, Tagmose TM, inventors; Novo Nordisk As, assignee. Acylated single chain insulin. Patent WO2007104738A3 (EP1996709A2, US20090099065). 2008.
   Google Scholar
• Olsen HB, Kjeldsen TB, Balschmidt P, et al., inventors; Novo Nordisk A/S, assignee. Rapid acting insulin analogues. Patent WO2009021955A1 (EP2178909B1, US8575096). 2009.
   Google Scholar
• Brocard-Masson C, Bonnin I, Dumas B, inventors; Sanofi, assignee. Process for preparing genetically transformed yeasts capable of producing a molecule of interest at a high titre. Patent US20140186885A1 (EP2723868A1, WO2012175453A1). 2014.
   Google Scholar
• Rhee SK, Kana HA, Chung BH, et al., inventors; Dong Kook Pharmaceutical Co., Ltd., Korea Research Institute of Bioscience and Biotechnology, assignee. Yeast transformant producing recombinant human parathyroid hormone and method for producing the hormone. Patent EP1313848B1 (US20040029252, WO2002018570A1). 2006.
   Google Scholar
• Katz M, Smits HP, Förster J, et al., inventors; Evolva Sa, assignee. Metabolically engineered cells for the production of resveratrol or an oligomeric or glycosidically-bound derivative thereof. Patent US8895287B2 (EP1856251B1, WO2006089898A1). 2014.
   Google Scholar
• Dorin G, Henry R, inventors; Amyris Biotechnologies, Inc., assignee. Compositions comprising artemisinic acid and methods of their preparation. Patent WO2009085068A1. 2009.
   Google Scholar
• Akella R, Ranieri J, inventors; Zimmer Orthobiologics, Inc., assignee. Protein mixtures for wound healing. Patent US20060286157A1 (EP1328288A2, WO2002000244A3). 2006.
   Google Scholar
• Mashima Y, Kishimoto N, Tabuchi R, et al., inventors; R-Tech Ueno, Ltd., Mitsubishi Tanabe Pharma Corporation, assignee. Pharmaceutical composition for treatment of dry eye and/or corneal/conjunctival disorders. Patent WO2009139464A1 (EP2301561A4, US20110065642). 2009.
   Google Scholar
• Kobayashi KTGCC, Kuwae STGCC, Ooya TTGCC, et al., inventors; The Green Cross Corporation., assignee. Method for producing human serum albumin. Patent EP0504823A2 (US5334512). 1992.
   Google Scholar
• Bukrinski JT, Jensen MML, Dubey S, et al., inventors; Novozymes Biopharma Dk A/S, assignee. Albumin composition for preventing and/or reducing formation of peptide fibrils. Patent WO2014096440A3. 2014.
   Google Scholar
• Sheffield WP, inventor; Canadian Blood Services, Inc., assignee. Chimeric hirudin proteins. Patent US8569237B2 (EP2186826B1). 2013.
   Google Scholar
• Nakajou K, Hoashi Y, Kai T, et al., inventors; Nipro Corporation, assignee. Production of recombinant human hemoglobin using Pichia yeast. Patent US20090098607A1. 2009.
   Google Scholar
• Olazaran MG, Saldana HB, Salvado JMV, inventors; Universidad Autonoma De Nuevo Leon, assignee. Modified methylotrophic Pichia pastoris yeast which secretes human growth hormone. Patent US6342375B1 (EP0952158B1, WO1998020035A1). 2002.
   Google Scholar
• Olsen DR, Polarek JW, Yang C, inventors; Fibrogen Inc, assignee. Implantable collagen compositions. Patent WO2006052451A3 (EP1814606B1, US20060100138). 2006.
   Google Scholar
• Clark E, Beck T, Ghiorse JT, et al., inventors; Dyax Corp, Genzyme Corp, assignee. Formulations for ecallantide. Patent WO2007106746A3 (EP2001500A4, US20070213275). 2008.
   Google Scholar
• Govindappa N, Sreenivas S, Kanojia KN, et al., inventors; Biocon Limited, assignee. Process of expressing a fully folded functional two chain insulin glargine. Patent US9388227B2 (EP2831262A4, WO2013144685A1). 2016.
   Google Scholar
• Lohray B, Shah S, Pandit H, et al., inventors; Cadila Healthcare Limited, assignee. Method for producing recombinant human interferon alpha 2b polypeptide in Pichia pastoris. Patent US20060223145A1 (EP1556498A1, WO2004039996A1). 2006.
   Google Scholar
• Sahib MK, Raju EB, Shaligram US, inventors; Wockhardt Limited, assignee. Process for the extraction and isolation of insulin from recombinant sources. Patent WO2004050672A2 (EP1575967B1). 2004.
   Google Scholar
• Habermann P, inventor; Sanofi-Aventis Deutschland Gmbh, assignee. Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest. Patent US7638618B2 (US20030028001). 2009.
   Google Scholar
• Kang HA, Rhee SK, Sohn MJ, et al., inventors; Korea Research Institute of Bioscience and Biotechnology, Leadbio, Inc., Bioholdings Co., Ltd., assignee. Hansenula polymorpha yapsin deficient mutant strain and process for the preparation of recombinant proteins using the same. Patent US7262287B2 (EP1534835B1, WO2004003204A1). 2007.
   Google Scholar
• Persoon NLM, Van LRW, inventors; Gist-Brocades N.V., assignee. Production and purification of recombinant human interleukin-3 and muteins thereof. Patent WO1990010705A2 (EP0390252B1). 1990.
   Google Scholar
• Menart S, Bolotin M, inventors; Rhone-Poulenc Rorer S.A, assignee. K. lactis pyruvate-decarboxylase promoter gene and use thereof. Patent WO1994001569A1 (EP0651810B1, US5631143). 1994.
   Google Scholar
• Owen DJ, Stanislawski P, Giannis M, inventors; Starpharma Pty Ltd, assignee. Dendrimer-drug conjugates. Patent WO2015184510A1. 2015.
   Google Scholar
• Ofoghi H, Rouhvand F. Intracellular expression of human calcitonin gene in yeast cells: potential application as functional food. Göteborg, Sweden: Publisher; 2003.
   Google Scholar
• Prevatt WD, Sreekrishna K, inventors; Research Corporation Technologies, Inc., assignee. Expression of human serum albumin in Pichia pastoris. Patent US5330901A (EP0510678A2). 1994.
   Google Scholar
• Hunter MGBBPL, Woods NRBBPL, inventors; Isis Innovation Limited, assignee. Expression of beta-2-microglobulin in Pichia pastoris. Patent EP0692027 B1 (US20020123108). 2004.
   Google Scholar
• Li Z, Parker M, inventors; University of the Sciences of Philadelphia, assignee. Compositions and methods of using therapeutic P53 peptides and analogues. Patent US20160145314A1 (WO2016081897A1). 2016.
   Google Scholar
• Salehzadeh A, Ofoghi H, Roohvand F, et al. Human calcitonin (hCT) gene expression and secretion by Pichia pastoris. Romanian Biotechnological Letters. 2012;17:7037.
   Web of Science ®Google Scholar
• Salehzadeh A, Ofoghi H, Roohvand F, et al. Intracellular expression of human calcitonin (hCT) gene in the methylotrophic yeast, Pichia pastoris. Afr J Biotechnol. 2011;10:12691.
   Google Scholar
• Mashayekhi MR, Zarghami N, Azizi M, et al. Subcloning and expression of human alpha-fetoprotein gene in Pichia pastoris. Afr J Biotechnol. 2006;5:321.
   Google Scholar
• Rubido JA, Perez EI, Mato YL, et al., inventors; Pharmaceutical compositions for therapeutic use. Patent US20070275012A1 (EP1676587A1, WO2005037311A1). 2007.
   Google Scholar
• Yum JS, Ahn BC, Jo HJ, et al., inventors; Dobeel Co., Ltd., assignee. An HBV vaccine and a process of preparing the same. Patent WO200809397A1 (EP2114450B1, US8216589). 2008.
   Google Scholar
• Garçon N, Stern PL, Cunningham AL, et al. Understanding modern vaccines: perspectives in vaccinology. New York, USA: Elsevier; 2011.
   Google Scholar
• Rutter WJ, Valenzuela PDT, Hall BD, et al., inventors; The Regents of The University Of California, assignee. Synthesis of human virus antigens by yeast. Patent US6544757B1 (US6475489). 1988.
   Google Scholar
• Lobaina Y, Hardtke S, Wedemeyer H, et al. In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015;63:320–327.
   PubMed Web of Science ®Google Scholar
• Joyce JG, George HA, Hofman KJ, et al., inventors; Merck & Co., Inc., assignee. Recombinant human papillomavirus type 18 vaccine. Patent US5820870A. 1998.
   Google Scholar
• Jansen KU, Cook III JC, George HA, et al., inventors; Merck & Co. Inc., assignee. Recombinant papillomavirus vaccines. Patent US5888516A. 1999.
   Google Scholar
• Cook III JC, inventor; Merck & Co., Inc., assignee. Process for purifying human papillomavirus virus-like particles. Patent US6602697B1 (WO2000009671A1). 2003.
   Google Scholar
• Jansen KU, Schultz LD, Neeper MP, et al., inventors; Merck Sharp & Dohme Corp., assignee. Optimized expression of HPV 31 L1 in yeast. Patent US7482428B2 (WO2004084831A3, EP1608767B1). 2009.
   Google Scholar
• Bryan JT, Brownlow M, Schultz L, et al., inventors; Merck Sharp & Dohme Corp., assignee. Optimized expression of HPV 58 L1 in yeast. Patent US20070036824A1 (EP1687329B8, WO2005047315A3). 2007.
   Google Scholar
• Bryan JT, Brownlow MK, Schultz LD, et al., inventors; Merck & Co., Inc., assignee. Optimized expression of HPV 45 L1 in yeast. Patent US7482015 B2 (EP1673106B1, WO2005032586A1). 2009.
   Google Scholar
• Bryan JT, Brownlow MK, Schultz LD, et al., inventors; Merck Sharp & Dohme Corp., assignee. Optimized expression of HPV 52 L1 in yeast. Patent US7744892B2 (WO2005097821A1). 2010.
   Google Scholar
• Kaslow DG, Barr PJ, inventors; The United States Of America, Represented by The Secretary, Department of Health and Human Services, Chiron Corporation, assignee. Transmission-blocking vaccine against malaria. Patent WO1992019758A1 (EP0584201B1, US5217898). 1992.
   Google Scholar
• Kumar R, Angov E, Kumar N. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding. Infect Immun. 2014;82:1453–1459.
   PubMed Web of Science ®Google Scholar
• Nussenzweig V, Barr P, inventors; New York University, Chiron Corporation, assignee. Vaccine against the sporozoite stage of malaria. Patent US4997647A. 1991.
   Google Scholar
• Li X, Huang J, Zhang M, et al. Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice. Vaccine. 2016;34:4501–4506.
   PubMed Web of Science ®Google Scholar
• Cohen JD, Marchand M, Ockenhouse CF, et al., inventors; Glaxosmithkline Biologicals Sa, assignee. Vaccines for malaria. Patent US20100062028A1 (EP2040743B1, WO2008009652A3). 2007.
   Google Scholar
• Vanloubbeeck Y, Pichyangkul S, Bayat B, et al. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine. 2013;31:6216–6224.
   PubMed Web of Science ®Google Scholar
• Blackman MJ, Holder AA, Kocken CHM, et al., inventors; Stichting Biomedical Primate R, assignee. Efficient expression of plasmodium apical membrane antigen 1 in yeast cells. Patent WO2002052014A3 (EP1346049B1, US7910330). 2002.
   Google Scholar
• Vicentin EC, Françoso KS, Rocha MV, et al. Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast. Infect Immun. 2014;82:1296–1307.
   PubMed Web of Science ®Google Scholar
• Pan W, inventor; Second Military Medical University, assignee. Preparation and usage of plasmodium fusion antigen. Patent US7101556B2 (EP1357128B1, WO2002072625A1). 2006.
   Google Scholar
• Hotez P, Loukas A, Zhan B, et al., inventors; The George Washington University, assignee. Human hookworm vaccine. Patent US20080166377A1 (US20100003285). 2007.
   Google Scholar
• Geldhof P, Borloo J, Claerebout E, et al., inventors; Universiteit Gent, assignee. Cooperia vaccine. Patent WO2014056885A1 (EP2906588A1, US20150265687). 2014.
   Google Scholar
• Hotez P, Loukas A, Pearson M, et al., inventors; The George Washington University, assignee. Multivalent antihelminthic vaccine. Patent WO2010002867A2 (US20110200640). 2010.
   Google Scholar
• Makoff AJ, Romanos MA, Clare JJ, et al., inventors; Evans Medical Limited, assignee. Expression of tetanus toxin fragment C in yeast. Patent US5389540A (EP0430645B1). 1995.
   Google Scholar
• Hepler R, Jansen K, Kelly R, et al., inventors; Merck & Co., Inc., assignee. Anthrax vaccine. Patent WO2005034841A3 (WO2005034841A2). 2005.
   Google Scholar
• O’Riordan AA, Morales VA, Mulligan L, et al. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine. 2012;30:3876–3884.
   PubMed Web of Science ®Google Scholar
• Zhou YZY, Li Z, Sheng W, inventors; Beijing industry university, assignee. Preparation method and application of recombinant enterovirus 71 type virus-like particle. Patent CN102839183A (CN101831410B). 2012.
   Google Scholar
• Li H-Y, Han J-F, Qin C-F, et al. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31:3281–3287.
   PubMed Web of Science ®Google Scholar
• Evans JD, Beatty NM, inventors; University of Pittsburgh - Of The Commonwealth System Of Higher Education, assignee. Yeast expression of flavivirus virus-like particles and use thereof. Patent US20140220061A1 (WO2013033362A1). 2014.
   Google Scholar
• Mani S, Tripathi L, Dhatchinamoorthy K, et al., inventors; International Centre For Genetic Engineering And Biotechnology, assignee. Pichia pastoris-expressed dengue virus like particles. Patent WO2014064707A1. 2014.
   Google Scholar
• Sablon E, Van Broekhoven A, Bosman F, et al., inventors; Innogenetics N.V., assignee. Constructs and methods for expression of recombinant HCV envelope proteins. Patent US7314925B2 (WO2002085932A2, EP1417298A2). 2008.
   Google Scholar
• Hauser P, Garcon NM-JC, Desmons P, inventors; Smithkline Beecham Biologicals S.A., assignee. Hepatitis B vaccine. Patent US5972346A (EP0810877B1). 1999.
   Google Scholar
• Medina-Selby A, inventor; Novartis Vaccines and Diagnostics, Inc., assignee. Expressing hepatitis B virus surface antigen for vaccine preparation. Patent US8119146B2 (EP2329843A3, WO2006113528A3). 2012.
   Google Scholar
• Ijm DV, Figdor CG, Ribas DB, inventors; Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre, assignee. Compositions and methods for generating an immune response in a subject. Patent US20120076827A1 (EP2173374A2, WO2009013018A3). 2010.
   Google Scholar
• Zhai L, Tumban E. Gardasil-9: A global survey of projected efficacy. Antiviral Res. 2016;130:101–109.
   PubMed Web of Science ®Google Scholar
• Covacci A, Bugnoli M, Telford J, et al., inventors; Chiron S.P.A., assignee. Helicobacter pylori proteins useful for vaccines and diagnostics. Patent US6090611A (EP0643770B1). 2000.
   Google Scholar
• Hsiao C-L, Mason BB, Davis AR, inventors; American Home Products Corporation, assignee. Production of rotavirus in yeast. Patent US4853333 A. 1989.
   Google Scholar
• Rodríguez-Limas WA, Tyo KE, Nielsen J, et al. Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb Cell Fact. 2011;10:1.
   PubMed Web of Science ®Google Scholar
• Mei Z, Donghu Y, Hai L, et al., inventors; (Beijing) Technology Co., Ltd, assignee. Virus-like particle hand-foot-and-mouth disease vaccine and preparation method thereof. Patent CN102533572 A. 2012.
   Google Scholar
• Zhao H, Li H-Y, Han J-F, et al. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against coxsackievirus A16 in mice. Appl Microbiol Biotechnol. 2013;97:10445–10452.
   PubMed Web of Science ®Google Scholar
• Ella KM, Kandaswamy S, inventors; Bharat Biotech International Limited, assignee. Vaccine composition comprising an inactivated chikungunya virus strain. Patent WO2012172574A1. 2012.
   Google Scholar
• Saraswat S, Athmaram T, Parida M, et al. Expression and characterization of yeast derived Chikungunya virus like particles (CHIK-VLPs) and its evaluation as a potential vaccine candidate. Plos Negl Trop Dis. 2016;10:e0004782.
   PubMed Web of Science ®Google Scholar
• Dalonso N, Goldman GH, Gern RM. Beta-(1–>3),(1–>6)-Glucans: medicinal activities, characterization, biosynthesis and new horizons. Appl Microbiol Biotechnol. 2015;99:7893–7906.
   PubMed Web of Science ®Google Scholar
• James M, inventor; James, Matthew (Bear, DE, US), assignee. Healthy composition for lowering cholesterol for use in foods, beverages, health supplements and medical foods. United States patent US20150125568 A1. 2015.
   Google Scholar
• Wolever TM, Tosh SM, Gibbs AL, et al. Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. Am J Clin Nutr. 2010;92:723–732.
   PubMed Web of Science ®Google Scholar
• Stier H, Ebbeskotte V, Gruenwald J. Immune-modulatory effects of dietary yeast beta-1, 3/1, 6-D-glucan. Nutr J. 2014;13:1.
   PubMed Web of Science ®Google Scholar
• Ross GD, inventor; University of Louisville Research Foundation, Inc. (Louisville, KY, US), assignee. Cancer therapy using beta glucan and antibodies. Patent US20150064199A1 (EP2181711A1). 2014.
   Google Scholar
• Ostroff GR, Ross GD, Ross TJK, inventors; Biopolymer Engineering, Inc., University of Louisville Research Foundation, Inc. assignee. Cancer therapy using whole glucan particles and antibodies. Patent EP2181711A1 (US20150064199, WO2004030613A3). 2010.
   Google Scholar
• Rice PJ, Adams EL, Ozment-Skelton T, et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther. 2005;314:1079–1086.
   PubMed Web of Science ®Google Scholar
• Graubaum H-J, Busch R, Stier H, et al. A double-blind, randomized, placebo-controlled nutritional study using an insoluble yeast beta-glucan to improve the immune defense system. Food Nutr Sci. 2012;3:738.
   Google Scholar
• Kelly GE, inventor; Novogen Research Pty. Ltd., assignee. Therapeutic uses of glucan. Patent US7622575 B2 (US20070142320, WO1996028476A1). 2009
   Google Scholar
• Kelly GE, inventor; Novogen Research Pty. Ltd., assignee. Methods of treating dermal ulcers using glucans. Patent US7648968B2 (EP0815144B1, WO1996028476A1). 2010
   Google Scholar
• Babineau TJ, Marcello P, Swails W, et al. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg. 1994;220:601.
   PubMed Web of Science ®Google Scholar
• Babineau TJ, Hackford A, Kenler A, et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg. 1994;129:1204–1210.
   PubMedGoogle Scholar
• Feldman S, Schwartz HI, Kalman DS, et al. Randomized phase II clinical trials of wellmune WGP [R] for immune support during cold and flu season. J Appl Res. 2009;9:30–43.
   Google Scholar
• Weitberg AB, inventor; Immudyne, Inc., assignee. Beta glucans and methods of use thereof. Patent US20100267661A1. 2010.
   Google Scholar
• Bose N, Gorden K, Chan S, et al., inventors; Biothera, Inc., assignee. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment. Patent WO2016007876A1. 2016.
   Google Scholar
• Ross GD, inventor; University of Louisville Research Foundation, Inc., assignee. Cancer therapy using beta glucan and antibodies. Patent US20150064199A1 (EP1539194A4, WO2004021994A2). 2015.
   Google Scholar
• Cheung N-KV, inventor; Sloan-Kettering Institute for Cancer Research, assignee. Therapy-enhancing glucan patent US20100273867A1 (EP1651676A4, WO2005018544A8). 2010.
   Google Scholar
• Demir G, Klein HO, Mandel-Molinas N, et al. Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. Int Immunopharmacol. 2007;7:113–116.
   PubMed Web of Science ®Google Scholar
• Gro HH, Lee CK, Specht CA. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded β-glucan particles. mbio 2010.
   Google Scholar
• Czech MP, Cohen JL, Aouadi M, et al., inventors; University of Massachusetts, assignee. Peptide-and amine-modified glucan particles for delivery of therapeutic cargoes. Patent WO2014134509 A2 (US20160184449, WO2014134509A3). 2014.
   Google Scholar
• Ostroff GR, Soto E, inventors; University of Massachusetts, assignee. Yeast cell wall particle for receptor-targeted nanoparticle delivery. Patent EP2603450A1 (US20160175251, WO2012024229A1). 2013.
   Google Scholar
• Huang H, Ostroff GR, Lee CK, et al. Characterization and optimization of the glucan particle-based vaccine platform. Clin Vaccine Immunol. 2013;20:1585–1591.
   PubMed Web of Science ®Google Scholar
• Stevens DA, Clemons KV, Luque JC, inventors; Antifungal vaccines with Saccharomyces cerevisiae. Patent US20080220023A1 (US20080220024). 2008.
   Google Scholar
• Franzusoff A, Duke R, King T, et al. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther. 2005;5:565–575.
   PubMed Web of Science ®Google Scholar
• Franzusoff A, Bellgrau D, inventors; Globeimmune, Inc, assignee. Yeast-based vaccines as immunotherapy. Patent US8734778B2 (EP2630969A1, WO2004058157A3). 2014.
   Google Scholar
• Munson S, Parker J, King TH, et al. Coupling innate and adaptive immunity with yeast-based cancer immunotherapy. Cancer Vaccines and Tumor Immunity: New Jersey, USA: John Wiley & Sons, Inc.; 2007. p. 131–149.
   Google Scholar
• Tanaka A, Jensen J, Prado R, et al. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther. 2011;18:827–834.
   PubMed Web of Science ®Google Scholar
• Palena C, Guo Z, Apelian D, et al., inventors; GlobeImmune, Inc, assignee. Yeast-Brachyury immunotherapeutic compositions. Patent US9198941B2 (EP2685995A4, WO2012125998A1). 2015.
   Google Scholar
• Rodell TC, Apelian D, Palena C, et al., inventors; Globeimmune, Inc, assignee. Yeast-based immunotherapy for chordoma. Patent WO2014186047A1 (EP2976100A1). 2014.
   Google Scholar
• Franzusoff A, Guo Z, Schlom J, et al., inventors; Globeimmune, Inc, assignee. Yeast-MUC1 immunotherapeutic compositions and uses thereof. Patent US20130315941A1 (EP2744918A4, WO2013025972A1). 2013.
   Google Scholar
• Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20:332–342.
   PubMed Web of Science ®Google Scholar
• Bilusic M, Heery CR, Arlen PM, et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother. 2014;63:225–234.
   PubMed Web of Science ®Google Scholar
• Bellgrau D, King TH, inventors; Globeimmune, Inc, assignee. Yeast-based immunotherapy and type I interferon sensitivity. Patent WO2015157639A1. 2015.
   Google Scholar
• Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21:3226–3235.
   PubMed Web of Science ®Google Scholar
• Lu Y, Bellgrau D, Dwyer-Nield LD, et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 2004;64:5084–5088.
   PubMed Web of Science ®Google Scholar
• Chaft JE, Litvak A, Arcila ME, et al. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer. 2014;15:405–410.
   PubMed Web of Science ®Google Scholar
• Stubbs A, Martin K, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med. 2001;7:625–629.
   PubMed Web of Science ®Google Scholar
• Duke RC, Bellgrau D, Franzusoff A, et al., inventors; Globeimmune, Inc, assignee. Yeast-HIV antigen compositions and methods of using the same. Patent US20130052220A1 (US20060104986, WO2002039951A2). 2013.
   Google Scholar
• Sasagawa T, Tohda H, Hama Y, inventors; Asahi Glass Company, Ltd., assignee. Human papillomavirus vaccine for oral administration. Patent US8282936 B2 (EP1790332B1, WO2006028214A1). 2012.
   Google Scholar
• Bolhassani A, Muller M, Roohvand F, et al. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania. Hum Vaccin Immunother. 2014;10:3499–3508.
   PubMed Web of Science ®Google Scholar
• Th K, Guo Z, Im O, inventors; Globeimmune, Inc, assignee. Compositions and methods for the treatment or prevention of tuberculosis. Patent US20160213767A1. 2014.
   Google Scholar
• Assis-Marques MA, Oliveira AF, Ruas LP, et al. Saccharomyces cerevisiae expressing Gp43 protects mice against Paracoccidioides brasiliensis infection. Plos One. 2015;10:e0120201.
   PubMed Web of Science ®Google Scholar
• Jacob D, Ruffie C, Dubois M, et al. Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens. Plos One. 2014;9:e86658.
   PubMed Web of Science ®Google Scholar
• Duke RC, Franzusoff A, Haller A, et al., inventors; Globeimmune, Inc, assignee. Yeast-based vaccine for inducing an immune response. Patent WO2007092792A3 (EP2468296A3). 2007.
   Google Scholar
• Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther. 2009;11:456–462.
   PubMed Web of Science ®Google Scholar
• Haller AA, Lauer GM, King TH, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007;25:1452–1463.
   PubMed Web of Science ®Google Scholar
• Apelian D, King TH, Guo Z, et al., inventors; Globeimmune, Inc, assignee. Compositions and methods for the treatment or prevention of hepatitis B virus infection. Patent US9428556B2 (WO2012109404A1, EP2672991A4). 2016.
   Google Scholar
• Lok AS, Pan CQ, Han SB, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016; 65(3): 509-516.
   PubMed Web of Science ®Google Scholar
• Howland WH, Lioyd O, Wittrup KD, inventors; Ludwig Institute for Cancer Research, Massachusetts Institute of Technology, assignee. Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens. Patent US20080171059A1 (WO2008019366A3). 2008.
   Google Scholar
• Shibasaki S, Aoki W, Nomura T, et al. An oral vaccine against candidiasis generated by a yeast molecular display system. Pathog Dis. 2013;69:262–268.
   PubMed Web of Science ®Google Scholar
• Apelian D, Franzusoff A, Rodell TC, inventors; Globeimmune, Inc, assignee. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer patent US8501167B2 (EP2134358A1, WO2008115610A1). 2013.
   Google Scholar
• Bui MR, Hodson V, King T, et al. Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine. 2010;28(37):6028–6035.
   PubMed Web of Science ®Google Scholar
• David ACC, Zhimin G, Thomas HK, inventors; Globeimmune, Inc, assignee. Yeast-based therapeutic for chronic hepatitis B infection. Patent US8877205B2 (EP2672991A1, EP2672991A4, US8722054). 2014.
   Google Scholar
• Duke RC, Franzusoff A, Haller AA, et al., inventors; Globeimmune, Inc, assignee. Yeast-based therapeutic for chronic hepatitis C infection. Patent 20100150963A1 (EP1809773A4, WO2006044923A3). 2010.
   Google Scholar
• Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part one: advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Pat. 2011;21:1811–1830.
   PubMed Web of Science ®Google Scholar
• Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat. 2012;22:391–415.
   PubMed Web of Science ®Google Scholar
• Liang TJ. Hepatitis B: the virus and disease. Hepatology (Baltimore, Md). 2009;49:S13–S21.
   PubMed Web of Science ®Google Scholar
• Breunig K, Behrens SE, inventors; Martin-Luther-Universität Halle-Wittenberg, assignee. Vaccination by means of recombinant yeast by creation of a protective humoral immune response against defined antigens. Patent US20150190486 (EP2844759A1, WO2013107436A8). 2013.
   Google Scholar
• Zhao H, Wang Y, Ma Z, et al. Recombinant Kluyveromyces lactis expressing highly pathogenic porcine reproductive and respiratory syndrome virus GP5 elicits mucosal and cell-mediated immune responses in mice. J Vet Sci. 2014;15:199–208.
   PubMed Web of Science ®Google Scholar
• Walch B, Breinig T, Schmitt M, et al. Delivery of functional DNA and messenger RNA to mammalian phagocytic cells by recombinant yeast. Gene Ther. 2012;19:237–245.
   PubMed Web of Science ®Google Scholar
• Xu K, Liu Z, Zhang L, et al. SiRNA in vivo-targeted delivery to murine dendritic cells by oral administration of recombinant yeast. Sirna Delivery Methods: Methods and Protocols. 2016; 1364:165–181.
   Google Scholar
• Zhang L, Zhang T, Wang L, et al. In vivo targeted delivery of CD40 shRNA to mouse intestinal dendritic cells by oral administration of recombinant Sacchromyces cerevisiae. Gene Ther. 2014;21:709–714.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Liu Y, Zhang XEA, inventors; NWAFU, assignee. Preparation method and application of novel oral DNA (deoxyribonucleic acid) vaccine adopting DNA fragments carried by oral yeast and used for aquatic animals. Patent CN104857507A. 2015.
   Google Scholar
• Zhang ZZ, Shao S, Xu K, et al., inventors; NWAFU, assignee. An oral recombinant yeast and mediated shRNA targeting intestinal DC presenting applications. Patent CN103695327B. 2016.
   Google Scholar
• Ueda M. Establishment of cell surface engineering and its development. Biosci Biotechnol Biochem. 2016; 80(7): 1–11.
   Web of Science ®Google Scholar
• Farmani J, Roohvand F, Safari M, et al. Cell surface display of Propionibacterium acnes linoleic acid isomerase by Pichia pastoris. Romanian Biotechnological Letters. 2013;18:8308.
   Web of Science ®Google Scholar
• Kevin CWP, Pingyu Z, Jian W, inventors; Merck Sharp & Dohme Corp, assignee. Eukaryotic cell display systems. Patent US20120329679A1 (US8637435, US20090163379). 2012.
   Google Scholar
• Wittrup KD, Kranz DM, Kieke M, et al., inventors; Board of trustees of the University of Illinois, assignee. Yeast cell surface display of proteins and uses thereof. Patent US6699658B1 (US6423538). 2004.
   Google Scholar
• Liu QZX, Li X, Huang J, inventors; Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, assignee. Yeast surface display of prawn white spot syndrome virus VP28 and application. Patent CN102653723 A. 2012.
   Google Scholar
• Liu QZX, Li X, Huang J, inventors; Yellow Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, assignee. Surface display and application of yeast of white spot syndrome virus (WSSV) VP37. Patent CN102021124A. 2011.
   Google Scholar
• Joo SYY, Sun HM, inventors; Univ Sungkyunkwan Found, assignee. A vaccine for treating or preventing pasteurellosis using a yeast surface-expression system. Patent WO2008153339. 2008
   Google Scholar
• Shin M-K, Yoo HS. Animal vaccines based on orally presented yeast recombinants. Vaccine. 2013;31:4287–4292.
   PubMed Web of Science ®Google Scholar